Why do so many biotech companies shy away from commercializing in Europe?
Lumanity’s Alex Fink shares important considerations on this topic in a short video discussion with Ed Saltzman at BIO-Europe. They discuss:
- Key complexities when considering European markets
- Recommendations on how to focus strategy to capitalize on the opportunity
- Why and what to consider, even when looking at an out-licensing approach
“Whatever [path you take] – investigating the economic potential in Europe, understanding the regulatory pathways, and understanding pricing reimbursement is the best way to maximize the value of your asset and company.”Alex Fink, Senior Vice President, Consulting